NPCE
NeuroPace, Inc.NASDAQHealthcare$14.65-0.34%ClosedMarket Cap: $493.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
25.10
P/S
4.92
EV/EBITDA
-39.19
DCF Value
$-33.88
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.2%
Operating Margin
-16.3%
Net Margin
-21.5%
ROE
-105.7%
ROA
-20.3%
ROIC
-18.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $26.6M | 77.4% | $-1.8M | $-2.7M | $-0.08 | — |
| FY 2025 | $100.0M | 77.2% | $-16.3M | $-21.5M | $-0.66 | — |
| Q3 2025 | $27.4M | 77.4% | $-2.6M | $-3.5M | $-0.11 | — |
| Q2 2025 | $23.5M | 77.1% | $-6.8M | $-8.7M | $-0.26 | — |
| Q1 2025 | $22.5M | 77.0% | $-5.1M | $-6.6M | $-0.21 | — |
| Q4 2024 | $21.5M | 75.4% | $-3.7M | $-5.3M | $-0.18 | — |
| FY 2024 | $79.9M | 73.9% | $-21.7M | $-27.1M | $-0.93 | — |
| Q3 2024 | $21.1M | 73.2% | $-4.2M | $-5.5M | $-0.19 | — |
| Q2 2024 | $19.3M | 73.4% | $-6.2M | $-7.5M | $-0.26 | — |
| Q1 2024 | $18.1M | 73.6% | $-7.5M | $-8.9M | $-0.32 | — |
| Q4 2023 | $18.0M | 75.2% | $-5.1M | $-6.2M | $-0.24 | — |
| FY 2023 | $65.4M | 73.6% | $-27.2M | $-33.0M | $-1.27 | — |